313 related articles for article (PubMed ID: 28663780)
1. New insights into the pathogenesis and prevention of tuberous sclerosis-associated neuropsychiatric disorders (TAND).
Gipson TT; Johnston MV
F1000Res; 2017; 6():. PubMed ID: 28663780
[TBL] [Abstract][Full Text] [Related]
2. Sirolimus relieves seizures and neuropsychiatric symptoms via changes of microglial polarity in tuberous sclerosis complex model mice.
Koike-Kumagai M; Fujimoto M; Wataya-Kaneda M
Neuropharmacology; 2022 Nov; 218():109203. PubMed ID: 35931213
[TBL] [Abstract][Full Text] [Related]
3. Tuberous sclerosis: a review of the past, present, and future.
Uysal SP; Şahin M
Turk J Med Sci; 2020 Nov; 50(SI-2):1665-1676. PubMed ID: 32222129
[TBL] [Abstract][Full Text] [Related]
4. TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study.
de Vries PJ; Belousova E; Benedik MP; Carter T; Cottin V; Curatolo P; Dahlin M; D'Amato L; d'Augères GB; Ferreira JC; Feucht M; Fladrowski C; Hertzberg C; Jozwiak S; Kingswood JC; Lawson JA; Macaya A; Marques R; Nabbout R; O'Callaghan F; Qin J; Sander V; Sauter M; Shah S; Takahashi Y; Touraine R; Youroukos S; Zonnenberg B; Jansen AC;
Orphanet J Rare Dis; 2018 Sep; 13(1):157. PubMed ID: 30201051
[TBL] [Abstract][Full Text] [Related]
5. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
6. The TAND checklist: a useful screening tool in children with tuberous sclerosis and neurofibromatosis type 1.
Cervi F; Saletti V; Turner K; Peron A; Bulgheroni S; Taddei M; La Briola F; Canevini MP; Vignoli A
Orphanet J Rare Dis; 2020 Sep; 15(1):237. PubMed ID: 32894194
[TBL] [Abstract][Full Text] [Related]
7. [Tuberous sclerosis complex: A review].
Pfirmann P; Combe C; Rigothier C
Rev Med Interne; 2021 Oct; 42(10):714-721. PubMed ID: 33836894
[TBL] [Abstract][Full Text] [Related]
8. Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation.
Hwang SK; Lee JH; Yang JE; Lim CS; Lee JA; Lee YS; Lee K; Kaang BK
Mol Brain; 2016 May; 9(1):56. PubMed ID: 27216612
[TBL] [Abstract][Full Text] [Related]
9. Neurological and neuropsychiatric aspects of tuberous sclerosis complex.
Curatolo P; Moavero R; de Vries PJ
Lancet Neurol; 2015 Jul; 14(7):733-45. PubMed ID: 26067126
[TBL] [Abstract][Full Text] [Related]
10. [Neuropsychiatric manifestations in Tuberous Sclerosis Complex (TSC): diagnostic guidelines, TAND concept and therapy with mTOR inhibitors].
Waltereit R; Feucht M; de Vries MC; Huemer J; Roessner V; de Vries PJ
Z Kinder Jugendpsychiatr Psychother; 2019 Mar; 47(2):139-153. PubMed ID: 30080117
[TBL] [Abstract][Full Text] [Related]
11. Profile of everolimus in the treatment of tuberous sclerosis complex: an evidence-based review of its place in therapy.
Capal JK; Franz DN
Neuropsychiatr Dis Treat; 2016; 12():2165-72. PubMed ID: 27601910
[TBL] [Abstract][Full Text] [Related]
12. Tuberous Sclerosis Complex-Associated Neuropsychiatric Disorders (TAND): New Findings on Age, Sex, and Genotype in Relation to Intellectual Phenotype.
de Vries PJ; Belousova E; Benedik MP; Carter T; Cottin V; Curatolo P; Dahlin M; D'Amato L; Beaure d'Augères G; Ferreira JC; Feucht M; Fladrowski C; Hertzberg C; Jozwiak S; Lawson JA; Macaya A; Marques R; Nabbout R; O'Callaghan F; Qin J; Sander V; Sauter M; Shah S; Takahashi Y; Touraine R; Youroukos S; Zonnenberg B; Kingswood JC; Jansen AC;
Front Neurol; 2020; 11():603. PubMed ID: 32733359
[No Abstract] [Full Text] [Related]
13. Tuberous sclerosis complex-associated neuropsychiatric disorder (TAND) in a low-resource setting - From seizure to psychosis: A case report.
Pokharel S; Jyotsana P; Maharjan RS; Singh R; Pandit K
Ann Med Surg (Lond); 2020 Dec; 60():734-736. PubMed ID: 33425343
[TBL] [Abstract][Full Text] [Related]
14. Tuberous sclerosis complex.
Henske EP; Jóźwiak S; Kingswood JC; Sampson JR; Thiele EA
Nat Rev Dis Primers; 2016 May; 2():16035. PubMed ID: 27226234
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for the development of autism spectrum disorder in children with tuberous sclerosis complex: protocol for a systematic review.
Mitchell R; Barton S; Harvey AS; Williams K
Syst Rev; 2017 Mar; 6(1):49. PubMed ID: 28270230
[TBL] [Abstract][Full Text] [Related]
16. mTOR Inhibitors in Tuberous Sclerosis Complex.
Curatolo P; Moavero R
Curr Neuropharmacol; 2012 Dec; 10(4):404-15. PubMed ID: 23730262
[TBL] [Abstract][Full Text] [Related]
17. Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures.
Lechuga L; Franz DN
Expert Rev Neurother; 2019 Oct; 19(10):913-925. PubMed ID: 31335226
[No Abstract] [Full Text] [Related]
18. Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex.
Franz DN
Biologics; 2013; 7():211-21. PubMed ID: 24143074
[TBL] [Abstract][Full Text] [Related]
19. The role of glia in epilepsy, intellectual disability, and other neurodevelopmental disorders in tuberous sclerosis complex.
Wong M
J Neurodev Disord; 2019 Dec; 11(1):30. PubMed ID: 31838997
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
